ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 560

Proteomic Profiling of Synovial Fluid Reveals Candidate Psoriatic Arthritis Biomarkers

Daniela Cretu1, Ihor Batruch2, Punit Saraon3, Dafna D. Gladman4, Fawnda Pellett5, Eleftherios Diamandis6 and Vinod Chandran7, 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada, 2Department of Pathology and Lab Medicine,, Mount Sinai Hospital, Toronto, ON, Canada, 3Department of Pathology and Lab Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 4Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 5Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 7Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, proteomics, psoriatic arthritis and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in patients seen in dermatology clinics and identifying soluble biomarkers for PsA will help in screening psoriasis patients for appropriate referral to a rheumatologist, as well as provide further insight into disease pathogenesis. However, identification of novel biomarkers in peripheral blood is difficult and unreliable. Potential PsA biomarkers are likely to originate in sites of inflammation such as inflamed joints and subsequently enter systemic circulation. Our purpose was to identify candidate PsA biomarkers by conducting high-throughput quantitative proteomic analysis of synovial fluid from inflammatory and non-inflammatory arthritides.

Methods: Using strong cation exchange chromatography, followed by LC-MS/MS on an LTQ-Orbitrap mass spectrometer in conjunction with database searching for protein identification and quantification, we extensively characterized the proteomes of SF from 3 individual PsA patients, as well as 2 Rheumatoid Arthritis (RA), 2 Gout, 3 Late Osteoarthritis (LOA), and 3 pooled non-inflammatory (NI) controls. All samples were analysed in triplicates, and extracted ion current (XIC) intensities were used to calculate protein abundance ratios. Two strategies were then employed for identification of candidate biomarkers: (1) examination of differential protein expression between the PsA, RA, Gout, LOA, and Non-Inflammatory controls, and (2) tissue specificity analysis through mining of publicly available databases

Results: A total of 594 non-redundant proteins were identified with one peptide (384 with two-peptides or more) in SF from all arthritis subsets, with a false discovery rate <1.5%. Of the 521 high-confidence proteins that were quantified from all patient groups, there were significant quantitative differences in 89 PsA SF-derived proteins compared to other arthritides. Following additional manual filtering, we obtained a preliminary list of 35 proteins as increased in PsA compared to all arthritic and non-inflammatory controls. Gene ontology (GO) analysis classified these proteins into categories pertaining to five main biological processes: complement activation, defense response, immunoglobulin mediated response, response to wounding, and extracellular matrix remodelling, all of which are attributes of PsA. The candidate proteins include also COMP, CD14, and MMP2, all of which have been previously investigated as PsA biomarkers.

Conclusion: Quantitative proteomic profiling of synovial fluid has the potential to identify candidate PsA screening biomarkers. Verification and validation of these markers in SF and serum, respectively, is essential and is currently under way.


Disclosure:

D. Cretu,
None;

I. Batruch,
None;

P. Saraon,
None;

D. D. Gladman,
None;

F. Pellett,
None;

E. Diamandis,
None;

V. Chandran,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-profiling-of-synovial-fluid-reveals-candidate-psoriatic-arthritis-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology